ライフサイエンスコーパス: disease severity

1 rinflammation and coagulopathy contribute to disease severity.

2 nd epigenetic signatures associated with RSV disease severity.

3 t the magnitude of this peak is dependent on disease severity.

4 lobule VI of the cerebellum and exacerbated disease severity.

5 ores to identify corresponding biomarkers of disease severity.

6 e patients with AD, and this correlated with disease severity.

7 cularization of small pulmonary arteries and disease severity.

8 lmost independent of patient cooperation and disease severity.

9 in COVID-19-infected patients in relation to disease severity.

10 as the role of viral coinfection in COVID-19 disease severity.

11 lis-infected gingival tissues, and increases disease severity.

12 ng immune phenotypes and degrees of COVID-19 disease severity.

13 inophils in mitigating C. difficile-mediated disease severity.

14 o eyes from the Chr1-risk group with similar disease severity.

15 g domain are significantly correlated to the disease severity.

16 this reduction as the primary determinant of disease severity.

17 neal thickness, follow-up time, and baseline disease severity.

18 antibody levels are associated with elevated disease severity.

19 ission was predictive of clinical course and disease severity.

20 identified as biomarkers with concordance to disease severity.

21 y of classical risk factors, including liver disease severity.

22 ctors to viral susceptibility, immunity, and disease severity.

23 antibodies were associated with features of disease severity.

24 (6MWT), and determine their association with disease severity.

25 onia and three-fourths used CT for assessing disease severity.

26 ays reduced ATPase activity), which predicts disease severity.

27 dance post-FMT was indicative of ameliorated disease severity.

28 NESp strains lack capsule that may increase disease severity.

29 es may be biased by treatment indication and disease severity.

30 y not vary by age, sex, symptom duration, or disease severity.

31 patients with renal fibrosis correlated with disease severity.

32 with a bimodal distribution correlating with disease severity.

33 ronger antibody response was associated with disease severity.

34 ication and neutrophils do not contribute to disease severity.

35 explored difference between men and women in disease severity.

36 ells from arthritis patients correlated with disease severity.

37 ePAL), which is itself the best predictor of disease severity.

38 on that is not significantly associated with disease severity.

39 -BB and IL-1RA significantly correlated with disease severity.

40 arker for diagnosis and to monitor change in disease severity.

41 the most difficult patients in whom to judge disease severity.

42 ivation pattern in blood, which changes with disease severity.

43 henotypes emerge and amplify with increasing disease severity.

44 its immunogenicity, leading to an impact on disease severity.

45 arious lesions and associated with increased disease severity.

46 des difficile infection (CDI), regardless of disease severity.

47 t that this may be a contributory factor for disease severity.

48 s among individuals with different levels of disease severity.

49 esiding in obese environments may accelerate disease severity.

50 ve measure to prioritize patients based upon disease severity.

51 included additional measures of itching and disease severity.

52 T cells increases Th1 responses and augments disease severity.

53 therapy with standard antibiotics to reduce disease severity.

54 , a subset of which may be useful to predict disease severity.

55 ry tract viral loads, but not with increased disease severity.

56 in low-income countries will also influence disease severity.

57 ound diagnostic thresholds used to determine disease severity.

58 om PMF patients correlates with fibrosis and disease severity.

59 metabolism, replication, immune evasion, and disease severity.

60 nexhausted Tc17 cell subsets associated with disease severity.

61 tigen-specific immune responses and COVID-19 disease severity.

62 sclerosis and are proposed as a predictor of disease severity.

63 te to preventing infection and modulation of disease severity.

64 culture positivity, adjusted for markers of disease severity.

65 tiviral response potentially contributing to disease severity.

66 ant to evaluate the effect of vaccination on disease severity.

67 ing the periodontal status and the extent of disease severity.

68 aptive immune pathways to profoundly advance disease severity.

69 mmunohistochemistry and were correlated with disease severity.

70 es due to age and sex that may contribute to disease severity.

71 tes on factor B, including one correlated to disease severity.

72 executive function, anxiety, depression and disease severity.

73 ng C. difficile infection greatly influences disease severity.

74 y tract infections with different degrees of disease severity.

75 ates in infection control but contributes to disease severity.

76 e androgen levels are associated with higher disease severity.

77 d COPD exacerbations and its relationship to disease severity.

78 nd intraoperative events are associated with disease severity.

79 ve or pathogenic immune responses related to disease severity.

80 RS-CoV-2-reactive CD4(+) T cells in distinct disease severities.

81 Raman spectroscopy, for assessing endoscopic disease severity according to the four-level Mayo subsco

82 n anti-DENV antibody titers, viral load, and disease severity among 133 dengue cases in a Nicaraguan

83 lyzed the association between viral load and disease severity among children who participated in a pr

84 We also compared in-hospital disease severity among groups employing an ordinal scale

85 g digital divides among older adults, across disease severities and socioeconomic distributions.

86 with cognition (processing speed), clinical disease severity and a putative plasma biomarker of dise

87 data support angiopoietin-2 as a measure of disease severity and a risk factor for long-term cogniti

88 d temporal/epidemiological trends relate and disease severity and adverse outcomes is incompletely un

89 se technology system, stratified by baseline disease severity and age.

90 utic administration of activin-A ameliorates disease severity and alleviates CNS immunopathology and

91 ctivation in oligodendrocytes attenuated EAE disease severity and ameliorated EAE-induced oligodendro

92 dentified IL-17A and KLK-7 as biomarkers for disease severity and apremilast pharmacodynamic effect i

93 Growth impairment was determined by disease severity and associated with reduced or borderli

94 etes in its presymptomatic stages may reduce disease severity and burden on a population level.

95 easures of cardiac morphology that relate to disease severity and clinical outcomes in neonates with

96 linical AD and significantly correlated with disease severity and complement activation.

97 hese features contribute toward variation in disease severity and confound genotype-to-phenotype anal

98 culated for patients with various degrees of disease severity and controls.

99 ient's history, most recent colonoscopy, and disease severity and course.

100 se induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients.

101 nological pathways that likely contribute to disease severity and death.

102 ronavirus 2 (SARS-CoV-2) is a major cause of disease severity and death.

103 n sex and age, and men are at higher risk of disease severity and death.(C) RSNA, 2020.

104 we aimed to evaluate the role of RSV in ARI disease severity and determine factors associated with i

105 mmatory biomarkers enhance associations with disease severity and hemorrhage.

106 tent Ss infection is associated with greater disease severity and higher bacterial burden in PTB.

107 We also collected data about disease severity and household demographics and assets.

108 rly reports suggested an association between disease severity and hypertension but did not account fo

109 gnaling significantly reduced TcdA/B-induced disease severity and immune responses in these mice.

110 IPR(319)) induced immune protection, reduced disease severity and improved survival after MHV-68 infe

111 ng in the differential diagnosis, in staging disease severity and in defining survival probability.

112 SF14, and oncostatin M-which correlated with disease severity and increased bacterial products in pla

113 s pathogenic toxins is a common indicator of disease severity and infection recurrence.

114 jury was correlated with putative markers of disease severity and inflammatory cytokines.

115 This increase strongly correlates with disease severity and is associated with elevated IL-6 an

116 is the most predictive marker of significant disease severity and is independent of the disease durat

117 We aimed to study the role of sex on disease severity and its correlation with CT findings.

118 The RNA model score was associated with disease severity and long-term survival (P = 4.66 x 10(-

119 owing evidence indicates that DVGs influence disease severity and may contribute to viral persistence

120 iomarkers show an association with increased disease severity and may help stratify patients and sele

121 ls may be utilized as a prognostic marker of disease severity and mortality in cryptococcal meningiti

122 b was associated with dramatically increased disease severity and mortality rates in humans and gnoto

123 re specifically for COVID-19 to help predict disease severity and mortality.

124 es from patients with AH and associated with disease severity and mortality.

125 raoperative events were associated with both disease severity and number of CVS components not achiev

126 nt to consider their impact both on COVID-19 disease severity and on viral spread in a population.

127 No information was available on disease severity and other confounding factors.

128 ut the mechanisms by which T cells influence disease severity and outcome are not well understood.

129 s quantifying variations in sensitivity with disease severity and over time.

130 can provide important information regarding disease severity and pathogenicity that is not otherwise

131 ns with cognitive impairment, mood, anxiety, disease severity and plasma lyso-Gb3 levels in 31 patien

132 ayer in humoral immunity, is associated with disease severity and plays an important role in AD patho

133 level markedly increased and correlated with disease severity and portal hypertension in patients wit

134 Aim of this study was to establish the disease severity and prognostic factors for disease outc

135 e may serve as an objective marker of ocular disease severity and progression and may be valuable too

136 diagnosis despite their role in determining disease severity and progression as well as in different

137 quantitative biomarkers for monitoring Fabry disease severity and progression.

138 , NA-based immunity has been shown to reduce disease severity and provide heterologous protection.

139 After adjusting for disease severity and relevant clinical factors, even sma

140 ed the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatme

141 ficient tools to assist in the assessment of disease severity and risk of AMD progression.

142 Further we examine whether it is linked to disease severity and specific degenerative changes in th

143 eration and differentiation, which increases disease severity and susceptibility to bacterial superin

144 S-CoV-2) infection, the relationship between disease severity and the host immune response is not ful

145 s and assess their association with COVID-19 disease severity and vaccine responses.

146 adiographic changes, and the relationship to disease severity and viral clearance in COVID-19 patient

147 Given the values of HRCT scores for both disease severity and viral clearance, a standardised HRC

148 ers to cause human infection, assessments of disease severity and viral replication kinetics in vivo

149 ase elevation is common in COVID-19, mirrors disease severity, and appears to reflect true hepatic in

150 tient characteristics, surrogate measures of disease severity, and clustering of outcomes within hosp

151 ts were used to determine differences across disease severity, and correlations were determined by us

152 ombine data on demography, contact patterns, disease severity, and health care capacity and quality t

153 analysis adjusting for comorbidities, liver disease severity, and other factors including gastroente

154 es in predicting COVID-19 pneumonia outcome, disease severity, and patient triage.(C) RSNA, 2020.

155 i-DENV antibody titer, serum viral load, and disease severity, and provides evidence for the mechanis

156 ntify biomarkers that predict host response, disease severity, and sequelae.

157 Age, household wealth, and disease severity are important determinants of healthcar

158 pectrum, we defined the relationship between disease severity as measured by several rating scales an

159 tractant CXCL1 during RSV infection affected disease severity as measured by weight loss.

160 Five of the 32 M4 lines showed less than 30% disease severity, as compared to the parental lines and

161 r are considered for surgery on the basis of disease severity assessed by ultrasound.

162 and healthy ageing; their role as markers of disease severity assessing the correlation with clinical

163 Second, CHIT1 reflected disease severity at a median 5 years later (p = 1.2E-04)

164 Acute severe colitis may be predicted by disease severity at onset and hypoalbuminemia.

165 tion date, ten individual comorbidities, and disease severity at presentation (as defined by hypoxia

166 ioeconomic factors are associated with worse disease severity at presentation in sarcoidosis, but the

167 These genetic data were compared with disease severity based on quantitative clinical paramete

168 ONSD values were correlated with disease severity, baseline brain magnetic resonance imag

169 Higher ONSD was associated with increased disease severity, brain imaging abnormalities, and incre

170 phy angiography shows some associations with disease severity, but it cannot be used unambiguously to

171 ccelerate disease progression and accentuate disease severity, but peripheral inflammatory processes

172 rus 2 in severe patients, and differences in disease severity by age and sex.

173 immunity by one pathogen may also affect the disease severity by other pathogens.

174 Disease severity captured by body mass index or TB disea

175 ere identified and linked to trajectories of disease severity change.

176 I, -0.67 to -0.11, p = 0.007) independent of disease severity (coma, number of seizures, acute kidney

177 we created a quantitative scale of clinical disease severity comprising of four major disease domain

178 cing data did not identify a strain genotype-disease severity correlation.

179 dies cannot determine causality, and current disease severity criteria were not available for patient

180 sized, the number of M2 macrophages rose and disease severity decreased.

181 Several medications demonstrated a disease severity-dependent association comparing general

182 biomarkers that provide shared link between disease severity, drug-induced pharmacodynamic effects a

183 ics (e.g., age, sex, comorbidity, referral), disease severity (e.g., triage level, fever duration, pr

184 ors, underlying host factors and markers for disease severity, e.g. requiring intensive care unit (IC

185 e, and expression correlated positively with disease severity (eosinophils/high-power field) and BZH.

186 uggesting that a reduced flow is a marker of disease severity even in patients with HG aortic stenosi

187 a need to identify new objective markers of disease severity for treatment stratification.

188 oughout diseased colon as well as changes in disease severity from IL22Fc treatment.

189 data demonstrate EAA in AUD and suggest that disease severity further accelerates epigenetic aging.

190 Disease severity, genomic diversity, age, and time spent

191 e identified, but with no difference between disease severity groups.

192 of observed mortality at highest deciles of disease severity (>= 27-40).

193 matory imbalance that is proportional to the disease severity hallmarks ZIKV microcephaly.

194 Plasma chemokines are biomarkers of greater disease severity, higher bacterial burden and delayed sp

195 rs were associated with asthma and sinonasal disease severity; however, lipid mediators showed less v

196 tients and their activity is associated with disease severity; however, the role of NK cells in the c

197 e, GSDMD deficiency substantially attenuates disease severity, implicating GSDMD-mediated release of

198 92 affected subjects revealed differences in disease severity in 51 countries from 17 world regions,

199 associated with increased acute respiratory disease severity in a cohort of previously healthy term

200 ignificantly reduced viral load and clinical disease severity in a dose-dependent manner.

201 an BSND significantly associates with kidney disease severity in a patient cohort with CEP290 mutatio

202 unteers, biomarkers of RSV susceptibility or disease severity in adults were: (1) lower anti-RSV neut

203 ransmission, and certain factors that impact disease severity in cattle parallel related facets of SA

204 y validated a score that accurately predicts disease severity in children with suspected CAP.

205 othrombotic dysregulation as a key marker of disease severity in COVID-19.

206 t and evaluated the predictability of GRS in disease severity in each age group.

207 t domestic water softeners improve objective disease severity in established AE.

208 trophil infiltration, T-cell activation, and disease severity in mice.

209 a cocktail of apoptotic metabolites reduced disease severity in mouse models of inflammatory arthrit

210 ed antibody levels have been associated with disease severity in nasal polyps, but upstream drivers o

211 vere itching, frequent flares, and increased disease severity in patients harboring the dermotype B m

212 gra and their relation to clinical scores of disease severity in patients with early or progressing P

213 ggesting it may be a good summary measure of disease severity in patients with USH2A-related retinal

214 ibiting CD8 T-cell cytotoxicity would reduce disease severity in patients.

215 e heterogeneous spectrum of presentation and disease severity in sepsis, as well as the complexity su

216 Reduced disease severity in the absence of the SOS1 variant sugg

217 cell responses occurred at the time of peak disease severity in the ceca and colons of all mice infe

218 of Staphylococcus aureus is associated with disease severity in the posterior thigh, but not in the

219 Vaccination reduced disease severity in wild-type (WT) and B2m KO mice but f

220 of individuals with asthma as a function of disease severity, in association with reduced T(reg) cel

221 with mortality but not with other metrics of disease severity including the degree of AS severity.

222 articipants with a diverse range of COVID-19 disease severity, including those requiring hospitalizat

223 erpesviridae, were associated with increased disease severity, indicated by a higher median Model for

224 CT-visible airways and its relationship with disease severity is unknown.Objectives: To measure CT to

225 hat prior ZIKV infection can modulate dengue disease severity like a DENV serotype poses challenges t

226 ication while simultaneously contributing to disease severity, likely reflecting their dual role as t

227 Although gut bacteria and fungi modulate disease severity, little is known about the effects of t

228 were associated with younger age, increased disease severity (lower glucose and hemoglobin concentra

229 al load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and

230 The score was evaluated against disease severity markers including survival analysis usi

231 Subset analyses examined HIV and HCV disease severity markers separately and jointly.

232 Disease severity may limit its use and surgeon oversight

233 ncentration correlated with several clinical disease severity measures, NfL and grey matter volume of

234 onships between mucus hyperconcentration and disease severity.Methods: Sputum samples were collected

235 ic allergy, lower FEV(1), radiographic sinus disease severity, nasal polyposis, and systemic corticos

236 was correlated positively with maximum IOP, disease severity, need for surgery, and number of affect

237 ts change during the disease course and with disease severity needs further study.

238 ce of myoclonus may aid in the assessment of disease severity, neurologic involvement, or prognostica

239 15-LO pathway and to the enhanced sinonasal disease severity observed in AERD.

240 0.94]) and after adjusting for the increased disease severity of patients who received a transfusion

241 Background Disease severity on chest radiographs has been associate

242 was trained to output a measure of pulmonary disease severity on CXRs (pulmonary x-ray severity (PXS)

243 Randomization was stratified according to disease severity on the basis of whether patients had ch

244 r did it appear to be related to measures of disease severity or control.

245 0(-5)), and plasma CCL20 was associated with disease severity (P = 4 x 10(-5)), although both require

246 lecystectomy videos were annotated by AI for disease severity (Parkland Scale), CVS achievement (Stra

247 After adjusting for disease severity, patients with antibiotics in their uri

248 Viral load (VL), disease severity, pharmacokinetics and safety were asses

249 to develop neuroimaging biomarkers to track disease severity, progression, and response to treatment

250 itch conditions and their associations with disease severity, QOL, health, and functioning.

251 positive SARS-CoV-2 RNAaemia correlated with disease severity, ranging from 53% in mild-to-moderate p

252 virus 2 (SARS-CoV-2) induces a wide range of disease severity, ranging from asymptomatic infection to

253 pectrum of presenting signs and symptoms and disease severity, ranging from fever and inflammation to

254 During dupilumab treatment, disease severity-related serum biomarkers (TARC, PARC, p

255 bly, CLP mice have delayed onset and reduced disease severity, relative to sham mice.

256 he combination of FTND and NCC in discerning disease severity (ROC curve analysis: AUC = 0.746, P = 0

257 using the World Health Organization COVID-19 disease severity scale.

258 cores correlated with radiographic pulmonary disease severity scores assigned to CXRs in the internal

259 e correlation of TCRbeta rearrangements with disease severity scores.

260 NCS alone, the addition of dupilumab reduced disease severity, significantly improved HRQoL, and impr

261 2 regions have different time courses in the disease severity spectrum.

262 onnaire is an easy method of identifying the disease severity stage, but polysomnography still remain

263 ents from the ZETA trial were divided into 4 disease severity subgroups: progression and symptoms, sy

264 of anti-NEAT antisera reduced mortality and disease severity, suggesting the protective component is

265 The relation between invariance and disease severity suggests that pathological motor variab

266 Despite refractory CS and disease severity, survival was favorable (on MCS 61%, 30

267 rols (SCA6b; 19-40%).SCA6a exhibited greater disease severity than SCA6b, as assessed with ICARS (p <

268 ntional management practice at either end of disease severity, the effect of algorithm-augmented care

269 o influenza virus infection as a function of disease severity using a ferret model and our lectin mic

270 ion studies were tested for association with disease severity using logistic regression adjusted for

271 djusting for demographic characteristics and disease severity using multivariable regression.

272 matter (GM) integrity of the cerebellum, and disease severity using the International Cooperative Ata

273 he Donor Quality Index (DQI) and recipients' disease severity, using the Model for End-Stage Liver Di

274 Outcomes included scores on the CRS disease severity visual analog scale (VAS), 22-item Sino

275 Disease severity was assessed; clinical symptoms were re

276 Additionally, increased disease severity was associated with globally slower flo

277 Reduction in disease severity was associated with reduced number, but

278 Disease severity was based on the visual field mean devi

279 Disease severity was categorized as mild-to-moderate in

280 Disease severity was correlated with results from viral

281 by administration of dextran sulfate sodium; disease severity was determined based on body weight, co

282 Disease severity was measured via immunohistochemical an

283 the effect of preinfection antibody titer on disease severity was mediated by viral load for each of

284 of 5 study sites, and at least one marker of disease severity was positively associated with healthca

285 Disease severity was similar in 4CMenB-immunised and uni

286 No differences in disease severity were noted among children infected with

287 nd inpatient settings, but no differences in disease severity were noted between RSV A and B.

288 Dyspnea, hospitalization, and disease severity were significantly associated with high

289 Wealth and disease severity were variably predictive of blood cultu

290 Plants showed less disease severity when sprayed with EPL solution, making

291 ng, immunosuppressed condition, and baseline disease severity), when compared with mortality in the c

292 correlated with various clinical markers of disease severity, whereas convalescent-phase SARS-CoV-2-

293 have increased IFNgamma production and less disease severity, whereas in an adoptive transfer model

294 rlier, at higher levels and independently of disease severity, whereas pro-inflammatory cytokines wer

295 lly measures radiographic COVID-19 pulmonary disease severity, which can be used to track disease cha

296 itic cell depletion, correlate strongly with disease severity; while a third set of traits, including

297 gnificantly reduce relapse rates and improve disease severity with acceptable tolerability.

298 disparities in HF incidence, prevalence, and disease severity, with a highlight on evolving knowledge

299 Validated biomarkers of RSV disease severity would benefit diagnostics, treatment de

300 Our hypothesis was that disease severity would correlate with enhanced Th2 cellu